EN | RU
EN | RU

Help Support

Back

Effectiveness of tocilizumab for treatment of hospitalized COVID-19 patients

hospitalized_COVID-10_patient hospitalized_COVID-10_patient
hospitalized_COVID-10_patient hospitalized_COVID-10_patient

A systematic review and meta-analysis aimed to explore tocilizumab's efficacy for COVID-19 management.

See All

Key take away

In hospitalized adults with SARS-CoV-2 infection, adjunctive tocilizumab significantly reduced short-term mortality, composite outcome of mortality or mechanical ventilation, severe side effects, hospitalization, serious infection, time-to-hospital discharge, and incidence of mechanical ventilation.

Background

A systematic review and meta-analysis aimed to explore tocilizumab's efficacy for COVID-19 management.

Method

Databases like World Health Organization International Clinical Trials Registry Platform, Cochrane Central Register of Controlled Trials, PubMed, and EMBASE were comprehensively explored for well-conducted trials in which coronavirus-infected people were randomized to get usual care alone or tocilizumab + usual care.

For pooling studies, a random-effects meta-analysis model was utilized. With the aid of Review Manager, data assessment was carried out. In total, 11 studies with 6579 people were incorporated and randomly segregated into tocilizumab (n=3406) and control (n=3173) groups.

Result

The use of monoclonal antibody tocilizumab substantially decreased the 28 to 30-day mortality (relative risk [RR] = 0.89), time-to-hospital discharge (hazard ratio = 1.30), incidence of mechanical ventilation (RR = 0.79), composite outcome of mechanical ventilation or death (RR = 0.81), serious infection (RR = 0.61), number of severe adverse events (RR = 0.64), intensive care unit admission (RR = 0.64).

Conclusion

Tocilizumab supplementation is beneficial for the management of hospitalized adults diagnosed with COVID-19. However, additional studies are needed for determining the optimal dose.

Source:

Medicine (Baltimore)

Article:

Effectiveness of tocilizumab in the treatment of hospitalized adults COVID-19: A systematic review and meta-analysis

Authors:

Jing Zhang et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: